Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
DBV Technologies SA – American ( (DBVT) ) has shared an update.
DBV Technologies announced positive results from the EPITOPE Phase 3 Open-Label Extension Study, demonstrating continued improvement in the efficacy and safety of the VIASKIN Peanut patch over 36 months. The study showed significant increases in the number of participants reaching higher eliciting doses and completing oral food challenges without adverse events. This data supports the company’s proposed labeling approach to the FDA and highlights the potential of VIASKIN Peanut as an effective treatment for peanut allergies in young children.
More about DBV Technologies SA – American
DBV Technologies SA is a clinical-stage biopharmaceutical company that focuses on developing treatments for food allergies. Its primary product is the VIASKIN Peanut patch, which is designed to treat peanut allergies in toddlers aged 1 to 3 years.
YTD Price Performance: 6.77%
Average Trading Volume: 256,437
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $68.9M
See more data about DBVT stock on TipRanks’ Stock Analysis page.
Trending Articles
- FuboTV (NYSE:FUBO) Lawsuit Faces New Challenge from DirecTV
- Tesla’s (NASDAQ:TSLA) Elon Musk Reveals AI Training Has Reached Its Limits
- Mario Gabelli Comes Back for Files in the Paramount (NASDAQ:PARA) Merger
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
